Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.46 |
| ▸ | CASP7 | P55210 | 4/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19989496 | 1.00 | CASP3 (0.46) | CASP3CASP7TRPA1MEN1ALDH1A1 | |
| SCHEMBL29859472 | 1.00 | CASP3 (0.46) | CASP3CASP7TRPA1MEN1ALDH1A1 | |
| SCHEMBL29859833 | 1.00 | CASP3 (0.46) | CASP3CASP7TRPA1MEN1ALDH1A1 | |
| SCHEMBL19989206 | 0.81 | MEN1 (0.49) | CASP3CASP7TRPA1MEN1ALDH1A1 | |
| SCHEMBL19989208 | 0.81 | MEN1 (0.49) | CASP3CASP7TRPA1MEN1ALDH1A1 | |
| SCHEMBL29859774 | 0.81 | MEN1 (0.49) | CASP3CASP7TRPA1MEN1ALDH1A1 | |
| SCHEMBL19989210 | 0.79 | LOX (0.51) | CASP3CASP7MEN1ALDH1A1LMNA | |
| SCHEMBL19989320 | 0.79 | LOX (0.51) | CASP3CASP7MEN1ALDH1A1LMNA | |
| SCHEMBL19989318 | 0.79 | LOX (0.51) | CASP3CASP7MEN1ALDH1A1LMNA | |
| SCHEMBL19989200 | 0.79 | CASP3 (0.47) | CASP3CASP7TRPA1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715608-B | Indazole compounds for use in tendon and/or ligament injuries | 诺华股份有限公司 | 2022-08-05 | — | — | CN | disclosed |
| EP-3515894-B1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2021-04-07 | — | — | EP | disclosed |
| EP-3515894-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | Novartis AG (CH) | 2019-07-31 | — | — | EP | disclosed |
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2018-03-29 | — | — | US | disclosed |
| WO-2018055550-A1 | INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | NOVARTIS AG (CH) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112907-B2 | Substituted indazoles for treating tendon and/or ligament injuries | SLC10A2, MMP1, TNNI3 | CASP3 408/4885CASP7 811/4885TRPA1 876/4885 |
| US-20180086716-A1 | Indazole Compounds for Use in Tendon and/or Ligament Injuries | MMP1, SLC10A2, TNNI3 | CASP3 815/4885CASP7 1083/4885TRPA1 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.